Navigation Links
Mylan Receives FDA Approval for Additional Strength of Generic Restoril(R)
Date:6/17/2009

Product shipment has begun

PITTSBURGH, June 17 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Temazepam Capsules USP, 22.5 mg. This strength is in addition to Mylan's currently marketed 15 mg and 30 mg strengths of the product.

Temazepam Capsules are the generic version of Mallinckrodt's Restoril(R), a sleep aid, which had total U.S. sales of approximately $6 million for the 12 months ending March 31, according to IMS Health. Mylan has begun shipping this product.

Currently, Mylan has 118 ANDAs pending FDA approval representing $82.7 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, which represent $16.7 billion in annual brand sales, according to IMS Health.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylans Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs
2. Mylan Announces Successful Matrix Delisting Offer
3. Mylan Announces Change in Board Leadership
4. Mylan Receives Final FDA Approvals for Generic Versions of Anti-Rejection Medication CellCept(R)
5. Mylan Schedules First Quarter 2009 Financial Results Conference Call and Live Webcast
6. Mylan Declares Quarterly Preferred Stock Dividend
7. Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
8. Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development
9. Mylan Announces Clarinex(R) Settlement Agreement
10. Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges
11. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... HIV/AIDS in South Africa may provide insight on how to ... areas of the world, which may have limited access to ... , A report on the global AIDS epidemic published ... pandemic, which has left 12 million children orphaned in Sub-Saharan ...
(Date:4/14/2014)... marvels of the 20th century, is currently losing a ... But scientists at the University of South Carolina have ... effectiveness, even against so-called "superbugs." , Bacteria have been ... of drugs since their first wide-scale use as antibiotics ...
(Date:4/14/2014)... ,, West Orange, NJ. April 10, 2014. John DeLuca, ... grant from Biogen Idec to study how persons with ... entitled "The Use of Actual Reality to Measure Everyday ... to conduct this research. Dr. DeLuca is senior VP ...
(Date:4/14/2014)... that the molecule, called microRNA 135b, is a vital ... the growth of bowel cancers. , Drugs targeted at ... cancer-causing mutations at once, while tests for it could ... believe. , The research was carried out by an ...
(Date:4/14/2014)... -- with symptoms increasing dramatically during some of the most ... study has found. , Depressive symptoms increased on average by ... these young men, who were around 25 years old when ... as their children. The results of the study were published ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:'MicroRNA' could be key target for bowel cancer treatment 2Health News:Young dads at high risk of depression, too 2
... with network providers, WOODLAND HILLS, Calif., April ... had the highest workplace,absenteeism at 2,761,000 lost work ... to cost employers $522 million annually. Anthem Blue ... to help identify and resolve issues that they ...
... from Innovative Program, SEATTLE, April 16 ... partnering with Technogym USA to bring the finest,fitness ... Technogym,The Wellness Company is the official fitness equipment ... of retirement living,communities are comparable to five-star hotels. ...
... should lead to more effective vaccines, researchers say , , WEDNESDAY, ... virus that produce seasonal flu epidemics start in East Asia ... world, researchers report. , And by focusing on new flu ... their forecast of seasonal flu strains and develop better vaccines, ...
... to extend the reach of their High ... Dropout Prevention ,Boost, Campaign, NEW YORK, April 16 The ... Call program as part of their "Boost",national public service advertising campaign ... of Amare Stoudemire, NBA,All-Star and Captain of the Phoenix Suns, the ...
... Hit Especially Hard, According to New NCPA,Study, DALLAS, ... the greatest penalties on low-income workers when they work,extra ... today by the,National Center for Policy Analysis., "The ... said NCPA Senior Fellow Laurence Kotlikoff, Boston University,professor and ...
... - Higher blood levels of an immune system protein ... disease, researchers at The University of Texas M. D. ... of the American Association for Cancer Research. , Their ... marker of poor prognosis also points to a molecular ...
Cached Medicine News:Health News:Anthem Blue Cross Employee Assistance Program to Help Reduce Employee Absenteeism 2Health News:AegisLiving Partners With Technogym USA to Enhance Wellness Throughout Its' Communities 2Health News:AegisLiving Partners With Technogym USA to Enhance Wellness Throughout Its' Communities 3Health News:Seasonal Flu Outbreaks Start in Asia: Study 2Health News:Seasonal Flu Outbreaks Start in Asia: Study 3Health News:Video: Phoenix Suns' Amare Stoudemire Kicks Off Program to Encourage Teens to 'Wake Up' and Go to School 2Health News:Video: Phoenix Suns' Amare Stoudemire Kicks Off Program to Encourage Teens to 'Wake Up' and Go to School 3Health News:Video: Phoenix Suns' Amare Stoudemire Kicks Off Program to Encourage Teens to 'Wake Up' and Go to School 4Health News:Video: Phoenix Suns' Amare Stoudemire Kicks Off Program to Encourage Teens to 'Wake Up' and Go to School 5Health News:Tax Rates Mean Extra Work Doesn't Pay 2Health News:Interleukin-12 indicates survival prospects for melanoma patients 2
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the 30 ... Miami Beach Convention Center from January 21-24. ... than 3,500 attendees from top pharmaceutical, fine chemical and specialty ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... VIENNA , April 23, 2010 AFFiRiS ... II clinical testing.,It may therefore be possible to confirm the ... start of this efficacy study comes only five,months after the ... in several disease areas and is currently developing a total ...
... LONDON , April 23, 2010 , , ... Managing uncertainty; A Migraine For Pharma Forecasters , , , ... has its up,s and down,s, with new markets,and products proving more complex and requiring sophisticated approaches to,forecast ... Dealing with uncertainties is no easy task. With ...
Cached Medicine Technology:AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 2AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 3AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 4MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit 2MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: